u/alemorg

I'm building a tool that aggregates public Reddit posts and comments mentioning narcolepsy medications to identify common side effects, treatment patterns, and efficacy of medications. I have made various posts (links below) recently on evidence based approach for most effective treatments, best supplement, potential causes of narcolepsy, etc.

This is NOT for commercial use.

I'm one person with narcolepsy trying to fill a research gap that affects me and everyone here. I know what it's like to suffer with this condition, it's derailed my whole life. Medication research for this condition is scarce (mostly research funded by big pharma and small patient sizes) and real patient experiences with drugs like Xywav, modafinil, pitolisant, and sunosi are scattered across thousands of Reddit posts. There is a wealth of data that I believe could change people's lives.

I have also cited Reddit's ToS that allows me to do this. The academic papers cited did not ask for permission nor give you the ability to opt out, but I am.

What the tool does

It analyzes public posts/comments that mention narcolepsy medications, extracts mentions of side effects, and produces aggregate-level output like:

- "Among 200 posts mentioning Xywav, nausea appeared in ~30%, anxiety in ~20%"
- "Modafinil sentiment breakdown: 60% positive, 25% neutral, 15% negative"

It does NOT identify individuals, publish quotes, or profile users. It reports patterns at the medication level.

Reddit ToS compliance

Reddit's Public Content Policy states: "you can use Reddit content for non-commercial uses, such as learning and community." This project is non-commercial. I'm also using the official API within rate limits, accessing only public subreddits, and not touching private, quarantined, or deleted content. Reddit's Data API Terms are also clear: no user content will be used for ML/AI training or any commercial purpose, which I am not doing.

Reddit ToS links:

• Public Content Policy: https://support.reddithelp.com/hc/en-us/articles/26410290525844-Public-Content-Policy
• Data API Terms: https://redditinc.com/policies/data-api-terms

This has been done before, by actual researchers

Reddit-based health research is published in peer-reviewed journals regularly. A few examples:

- Pleasants E, et al. (2023). "Exploring Language Used in Posts on r/birthcontrol." J Med Internet Res, 25, e46342.
- Johnson AK, et al. (2022). "STD-Related Reddit Posts During the COVID-19 Pandemic." J Med Internet Res, 24(10), e37258. PMID: 36219757.
- Heidari O, et al. (2024). "Personal Experiences With Xylazine and Behavior Change." J Addict Med, 19(2), 135-142. PMID: 39329377.
- Adams NN. (2024). "'Scraping' Reddit posts for academic research?" Int J Soc Res Methodol, 27(1), 47-62.
- Turcan E, McKeown K. (2019). "Dreaddit: A Reddit Dataset for Stress Analysis in Social Media." LOUHI 2019, 97-107.

I'm following the same methodology and ethical framework these papers used. The Adams (2024) paper specifically outlines the ethical considerations for Reddit based research, including consent, anonymization, and data handling, and my tool follows those recommendations.

How anonymization works

1. At collection: I only pull post text, subreddit name, month (not day), and score. Usernames, permalinks, profile URLs, avatars, flair, and user IDs are never stored. The raw API response is processed in memory and discarded immediately, nothing identifiable is stored.

2. Text scrubbing: A preprocessing pass strips direct identifiers (u/ handles, emails, phone numbers, URLs, clinic names, street addresses, exact dates). Quasi-identifiers like age, location, and employer are generalized (e.g. "29-year-old nurse in Boise" becomes "adult healthcare worker in western US").

3. Storage: Only the cleaned, de-identified analytic table is stored: subreddit, medication mention, side effect flag, month, and a sentiment score. No raw text. No way to trace anything back to a person.

4. Output: Only aggregate statistics. Minimum threshold of 10 posts per subgroup. No individual quotes, no verbatim text, no cross-tabulations that could isolate a single person.

Opt-in vs opt-out

Some people have asked about consent. Here's why I'm doing opt-out rather than opt-in:

Opt-in is not standard practice for secondary analysis of public social media data. None of the published studies I cited used opt-in consent, because Reddit posts are public by default, ethics boards routinely classify this as exempt research, and requiring opt-in would create massive selection bias (only the most motivated people respond, skewing the data). Once data is properly anonymized, informed consent becomes structurally impossible to retroactively apply, and that's accepted practice in health informatics research.

I'm offering opt-out because I think people deserve the option, even though it's not required by ToS or standard research practice. I’m trying to do this right when other academic papers have not, considering I am part of this community not just a researcher.

How opt-out will work

Because all data is fully anonymized at the point of collection (usernames are never stored long-term), implementing opt-out requires a specific pipeline: usernames collected during the scrape will be hashed, checked against the opt-out list, matching posts excluded, and then the hashing salt destroyed , meaning exclusion is applied and can't be reversed or abused. I will update everyone once the mechanism is finalized, including a submission form.

Links to my recent posts:

https://www.reddit.com/r/Narcolepsy/s/mqegrd6GpU

https://www.reddit.com/r/Narcolepsy/s/c5XsZo9Ol5

https://www.reddit.com/r/Narcolepsy/s/jrO1OPfQbl

https://www.reddit.com/r/Narcolepsy/s/egbb28hTJA

https://www.reddit.com/r/Narcolepsy/s/Gz2QWADyeN

https://www.reddit.com/r/Narcolepsy/s/FWxu8RVOZS

Just wanted to thank everyone for the positive comments I have received in my other posts. I also want to thank all the people who shared their personal experiences as that is very important. This post highlights the potential causes of narcolepsy and might shed some light on your journey and hopefully bring more understanding to your life. One thing I noted but wanted to repeat most of the research was done on European and Asian people, there is a huge gap in research for everyone else. Again please feel free to comments suggestions or let me know if there are any mistakes I need to correct.

Also currently I’m working on a post for research about children with narcolepsy, gender differences in narcolepsy (news flash, of course the research is centered around men and one ethnicity…), best medications for sleep (basically only sodium Oxybates), highest prevalence of comorbidities, and some miscellaneous research about narcolepsy. After I am done I want to build a Reddit sentimental analysis with the developer api key that filters through all the narcolepsy posts and comments so I can get a compilation of everyone’s subjective and anecdotal experiences. Also will probably run out of narcolepsy research so after I will research mental health disorders and then idk lol. Sorry that it’s so long. Go to the end of the post where it says key finding summary if you just want a brief overview.

1: HYPOCRETIN/OREXIN NEURON LOSS (The Core Pathology)

This is the most replicated finding in narcolepsy research. It has been confirmed across multiple independent laboratories, in postmortem tissue and in living patients via CSF measurement, for 25+ years with no credible contradiction.

Thannickal et al. 2000 (PMID 11055430): Postmortem hypothalamus, n = 3 NT1 brains versus 3 controls. Found an 85 to 95 percent reduction in hypocretin neuron count (p < 0.02). Remaining neurons were smaller and terminal bouton density was reduced. Melanin-concentrating hormone (MCH) neurons, which are intermixed with hypocretin neurons in the lateral hypothalamus, were completely spared. This proves the immune attack is selective, not general neurodegeneration. The n = 3 is small by modern standards but this finding has been replicated in over 50 postmortem brains across four independent laboratories since.

Nishino et al. 2000, Lancet (PMID 10615891): CSF hypocretin-1 was undetectable (< 40 pg/mL) in 7 of 9 NT1 patients (78 percent) and normal in all controls (p < 0.001). This was the first confirmation using an independent method, spinal fluid rather than brain autopsy. CSF hypocretin measurement has since been replicated hundreds of times and is now the diagnostic gold standard for NT1 per ICSD-3 criteria (cutoff ≤ 110 pg/mL).

Savvidou et al. 2013, Sleep (PMID 23288981): Showed that hypocretin deficiency develops during disease onset rather than being present from birth, establishing causation rather than just correlation. Exact onset-to-deficiency timeline statistics require full-text access, some articles are behind a paywall.

What makes this solid: The orexin neuron loss has been confirmed in more than 50 postmortem brains analyzed across labs at UCLA, Stanford, Leiden, and Tokyo. Every single NT1 brain studied shows severe loss. There is no contradicting finding after 25 years. Multiple independent methods (postmortem cell counting, CSF protein measurement, in situ hybridization) all converge on the same conclusion.

The limitations: Postmortem n is still small because hypothalamic autopsy tissue is scarce. Most brains studied were from end-stage disease, so the acute attack cannot be observed directly.

2: HLA-DQB1*06:02 (The Genetic Gate)

This is one of the strongest HLA-disease associations in all of medicine. It has been replicated in every ethnic population studied across dozens of independent cohorts over three decades.

Mignot et al. 1997 (PMID 9456467) and dozens of confirmations: 90 to 98 percent of NT1 patients carry HLA-DQB1*06:02 versus 12 to 25 percent of the general population, varying by ethnicity. The pooled odds ratio from European cohorts is approximately 30 (range across studies: 25 to 50). A negative DQB1*06:02 result has a negative predictive value above 99 percent in some cohorts, which means it essentially rules out NT1.

Zhang et al. 2025, PNAS (PMID 41364757): Largest transethnic narcolepsy GWAS ever conducted, pooling 5,339 cases from China, Europe, Korea, Japan, and the United States. Confirmed DQB1*06:02 as the primary risk allele across all populations and identified DQB1*03:01 as strongly affecting age of onset independently of DQA1 and ethnicity (p < 10^-8 after Bonferroni correction). Exact per-allele ORs require full-text access.

Ollila et al. 2015, American Journal of Human Genetics (PMID 25574827): Showed the HLA story is more nuanced. DQB1*06:02 homozygotes have approximately 2 times higher risk than heterozygotes carrying a neutral second DQB1 allele. Some DQB1 alleles — specifically DQB1*06:01, DQB1*06:03, and DQB1*05:01 — are actually protective (OR < 0.5). Exact OR and CI per allele require full-text access.

Capittini et al. 2018, Sleep Medicine (PMID 30321823): Meta-analysis quantifying diagnostic utility across four ethnic groups: Asians, Afro-Americans, Amerindians, and Caucasians. Pooled diagnostic sensitivity was 91 percent and specificity was 73 percent for detecting NT1. Sensitivity was highest in Caucasians and Asians and lower in African-Americans and Amerindians, consistent with the ethnic differences in DQB1*06:02 positivity rates discussed below. Exact CIs around sensitivity and specificity require full-text access.

What the numbers mean: This is a gate, not a trigger. Only about 1 percent of people who carry DQB1*06:02 ever develop narcolepsy. The allele is necessary but not sufficient. The question is what pushes that 1 percent through the gate, and that is where the environmental trigger evidence comes in.

DISCLAIMER: (The ethnic gap in the data matters). Most DQB1*06:02 research comes from European and Asian cohorts where positivity runs 90 to 98 percent. In a Brazilian study of 21 NT1 patients (Bacelar et al. 2024, PMID 39150697), only 61.9 percent carried DQB1*06:02 despite elevated odds versus controls (18.0 percent), which suggests other HLA alleles are contributing in admixed Latin American populations. African Americans show high DQB1*06:02 positivity (91 percent per Kawai et al. 2015, PMID 26158891) but are 4.5 times more likely to have NT1 without cataplexy than Caucasians, and their CSF hypocretin is more frequently low (93.9 percent vs 61.5 percent). Neither Black Americans, Indigenous Americans, nor admixed Latin American populations have been adequately studied for narcolepsy-specific HLA genetics. The 90 to 98 percent figure is a European and Asian finding, not a universal one.

The limitation: Genetic association does not equal causation. GWAS-level resolution tells us the allele is involved but cannot tell us the precise functional mechanism without complementary immunology studies.

3: INFECTION AS THE TRIGGER (H1N1 and Pandemrix)

The epidemiological evidence that narcolepsy onset follows infections, particularly H1N1 influenza, is extremely strong. This is arguably the best-established environmental trigger for any autoimmune disease.

Han, Mignot et al. 2011, Annals of Neurology (PMID 21866560): Analysis of 906 Chinese NT1 patients. Onset showed a strong seasonal pattern peaking in April through August (spring and summer months). Monthly onset rate correlated with influenza and upper airway infection rates at the population level. There was a roughly 6-month delay between the 2009 H1N1 pandemic peak in China and the narcolepsy onset peak, with a 3-fold increase in new-onset narcolepsy in 2010 versus the pre-pandemic baseline (cross-correlation showed a significant 5- to 7-month delay between the seasonal peak in influenza infections and peak in narcolepsy onset, p < 0.001). Critically, China did not use the Pandemrix vaccine, so this signal came from wild-type infection alone.

Multiple European Pandemrix studies 2012 to 2018: In Finland, Nohynek et al. 2012 (PMID 22470453) found a rate ratio of 12.7 (95% CI 6.1 to 30.8, p < 0.001) for childhood narcolepsy following the Pandemrix vaccination campaign (incidence 9.0 per 100,000 person-years in vaccinated versus 0.7 per 100,000 in unvaccinated), with a vaccine-attributable risk of 1 case per 16,000 vaccinated children aged 4 to 19 years. Sweden, Norway, the UK, Ireland, and France all independently reported 3 to 14-fold increases using different health systems and different study designs. Adult risk was elevated 2 to 7-fold. The signal was so strong that Finland suspended Pandemrix use in August 2010.

Sarkanen et al. 2018 (PMID 29855798): Review summarizing the Pandemrix-narcolepsy evidence across multiple countries. Pandemrix-triggered cases had more severe clinical presentations including younger age of onset, more psychiatric comorbidities, and more pronounced polysomnographic abnormalities compared with sporadic narcolepsy. The consistency of findings across independent health systems confirms these cases were genuine narcolepsy rather than misdiagnosis.

What makes this strong: Multi-country replication with different healthcare systems, different study designs, all pointing to the same conclusion. The temporal association was extremely tight with onset occurring 0 to 12 months post-vaccination. The Chinese data provides convergent evidence from wild-type infection without any vaccine confound. The 6-month delay between infection peak and onset peak matches the known timeline for autoimmune disease development.

The limitation: Only Pandemrix, which used the AS03 adjuvant (squalene plus alpha-tocopherol), was associated with narcolepsy. Other H1N1 vaccines were not. Why Arepanrix, same AS03 adjuvant, used in Canada, did not produce a narcolepsy signal remains debated. Vaarala et al. 2014, PLoS ONE (PMID 25501681): n = 47 children with Pandemrix-associated narcolepsy versus 57 healthy Pandemrix-vaccinated children. Found increased circulating IgG antibodies to Pandemrix H1N1 antigen in the narcolepsy group, and identified higher amounts of structurally altered viral nucleoprotein in Pandemrix compared to Arepanrix. This supports the molecular mimicry model by showing a physical antigenic difference between the two vaccines that could explain the different risk profiles. Exact antibody titer CIs require full-text access.

Stowe et al. 2020, PLoS Medicine (PMID 32926731): Reassessed narcolepsy risk 8 years after Pandemrix in England using a case-coverage design. The odds ratio for narcolepsy onset at any time after vaccination was 1.94 (95% CI 1.30 to 2.89), with the elevated risk period restricted to onsets within 12 months of vaccination. Important because it confirmed the risk was not just a short-term shift in diagnosis timing, the signal persisted as a long-term elevation rather than being explained by Pandemrix merely accelerating inevitable narcolepsy onset.

Ambati et al. 2015, Journal of Internal Medicine (PMID 25683265): n = 38 Pandemrix-vaccinated narcolepsy cases (all DQB1*06:02 positive) and 76 matched controls (23 DQB1*06:02 positive, 53 negative). IFN-γ production was significantly increased in response to streptococcus M6 serotype (p = 0.0065) and streptodornase B protein (p = 0.0050). T-cell recognition was confirmed at the single-cell level by intracellular cytokine staining (IL-2, IFN-γ, TNF-α, and IL-17). This suggests streptococcal infection may be an additional trigger beyond influenza, consistent with the broader post-infectious autoimmune model.

4: AUTOREACTIVE CD4+ T-CELLS TARGETING HYPOCRETIN (The Mechanism)

This is the mechanistic heart of the autoimmune model. These papers form a progressive chain of evidence from blood to brain.

Latorre, Sallusto, Mignot et al. 2018, Nature (PMID 30232458): n = 19 NT1 patients and 13 healthy controls. Used HLA-DQ0602 tetramers loaded with hypocretin peptides to detect autoreactive CD4+ T-cells. Found hypocretin-specific CD4+ T-cells in all 19 NT1 patients (100 percent) and in 0 of 13 controls (0 percent, p < 0.0001 by Fisher's exact test). Also detected CD8+ T-cells targeting hypocretin. Single-cell TCR sequencing revealed shared CDR3 motifs across patients. Tetramer technology is the gold standard for antigen-specific T-cell detection, and Nature is as credible as journals get. The limitation is that the T-cell responses were detected only in peripheral blood, not in brain tissue, so this does not prove these cells actually cross the blood-brain barrier and kill neurons in vivo.

Luo, Mignot et al. 2018, PNAS (PMID 30541895): n = 35 NT1 patients and 22 DQ0602 controls. Demonstrated that the C-amidated form of hypocretin peptides (HCRT-NH2), not the native form, are the autoantigens. HLA-DQ0602 binding to hypocretin peptides occurs in 98 percent of NT1 patients versus 25 percent of the general population due to DQB1*06:02 enrichment in patients. The key finding: influenza A hemagglutinin (pHA 273-287) and nucleoprotein (NP 17-31) peptides share sequence homology with HCRT-NH2. T-cells cross-reactive to both flu peptides and hypocretin peptides were found in NT1 patients. Single-cell TCR analysis showed identical CDR3-beta sequences in HCRT-NH2 and pHA tetramer-positive cells from the same patient. This is direct evidence of molecular mimicry: flu-specific T-cells cross-recognize hypocretin, explaining HOW an infection triggers autoimmunity. The limitation: the authors themselves noted they were unable to replicate some of the results, and sample processing differences may affect tetramer staining.

Shan, Fronczek, Lammers et al. 2026, Annals of Neurology (PMID 41830424): Postmortem NT1 hypothalamic tissue, n = 7 NT1 and 6 controls. Found an approximately 11-fold increase of CD4+ T-cells in the hypocretin region versus control hypothalami (p < 0.001). No corresponding increase in CD8+ T-cells was observed, suggesting CD4+ cells are the primary infiltrating cells. This is the first direct evidence of T-cell infiltration at the actual site of neuron loss in human brain, which closes a major gap in the autoimmune hypothesis. The limitation: postmortem tissue means end-stage disease, so the acute attack phase cannot be observed.

Jiang et al. 2019, Nature Communications (PMID 31748512): n = 15 NT1 patients. Demonstrated in vivo clonal expansion of hypocretin-specific CD4+ T-cells with a Th1/Th17 phenotype capable of crossing the blood-brain barrier. Hypocretin-specific T-cells recognized the same hypocretin peptides presented by DQ0602 across multiple patients, confirming a shared autoimmune mechanism rather than patient-specific random reactivity. Exact clonal frequency statistics require full-text access. Published in Nature Communications with the Mignot group. The limitation: n = 15 is modest and all were adult NT1.

Cogswell et al. 2019, Annals of Clinical and Translational Neurology (PMID 31730293): n = 27 children with NT1 versus 15 controls. Observed higher frequencies of IFN-γ-producing and TNF-α-producing CD4+ and CD8+ T-cells in response to orexin peptides in children with NT1. Important because it shows T-cell autoreactivity in children close to disease onset, which is when the autoimmune attack is most active. Exact fold-difference statistics require full-text access.

Bernard-Valnet et al. 2022, Brain (PMID 35552381): Mouse model study. Showed that influenza vaccination in DQ0602-transgenic mice induced autoreactive CD4+ T-cells targeting orexin neurons, leading to sleep fragmentation and sleep attacks. This is the closest thing to direct experimental proof that vaccination can trigger orexin neuron autoimmunity in a controlled setting. The limitation: this is a mouse model, not human data, and mouse immune responses do not always translate perfectly.

What the progression means: These papers together form an unusually complete causal chain spanning human blood, human brain, and a controlled mouse model. Autoreactive cells found in blood (Latorre 2018, 19/19 vs 0/13, p < 0.0001), molecular mimicry between flu and hypocretin demonstrated (Luo 2018), clonal expansion of these cells confirmed in patients (Jiang 2019), flu vaccine triggering the process shown in a mouse model (Bernard-Valnet 2022), and T-cells confirmed at the lesion site in human brain (Shan 2026, 11-fold increase, p < 0.001). The main remaining gap is proving these T-cells are directly responsible for neuron killing in humans, which would require an interventional study that is ethically impossible.

5: CD8+ T-CELLS (The Killer Cells)

Pedersen, Kornum et al. 2019, Nature Communications (PMID 30783092): n = 20 NT1 patients and 52 healthy controls. Screened 1,183 peptides from 7 proteins enriched in hypocretin neurons. Found CD8+ T-cells in NT1 patients that recognize peptides from HCRT, RFX4, and other hypocretin-neuron-enriched proteins. The frequency of autoreactive CD8+ T-cells was higher in NT1 patients than in controls. Importantly, healthy DQB1*06:02 carriers actually had lower frequencies of autoreactive CD8+ T-cells than both NT1 patients and non-carrier controls, suggesting active immune regulation in protected individuals. Exact frequency and fold-difference statistics require full-text access.

Why CD8+ matters: CD8+ T-cells are the cytotoxic killer cells. In the standard autoimmune model, CD4+ cells provide help and CD8+ cells execute the kill. Finding CD8+ autoreactivity makes the mechanistic story logically complete.

Luo et al. 2021, Scientific Reports (PMID 33837283): Extended the autoantigen search beyond hypocretin. Found T-cell reactivity to Regulatory Factor X4 (RFX4), a protein co-localized with hypocretin in orexin neurons, in NT1 patients. This suggests the autoimmune attack may target multiple proteins in orexin neurons, not just hypocretin peptides, which would explain the completeness of neuron destruction.

Huth et al. 2024, Journal of Autoimmunity (PMID 38663202): Single-cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset NT1. Found activated CD4+ T-cells and clonally expanded CD8+ T-cells in the CSF of recent-onset patients, showing the immune activity is not just in blood but in the central nervous system compartment. This is closer to the site of damage than any previous blood-based study.

The complication: Shan 2026 (Section 4) found CD4+ dominance, not CD8+ dominance, at the actual lesion site in postmortem brains. This creates a discrepancy. The field may be moving toward a CD4+ dominant model where CD4+ T-cells are themselves directly cytotoxic, or toward a model where CD8+ cells execute the kill and then leave the tissue while CD4+ cells remain. The CD8+ detection methodology using tetramers is also less well-established than the CD4+ equivalent.

The comprehensive reviews: Liblau, Latorre, Kornum, Dauvilliers, and Mignot 2023 in Nature Reviews Immunology (PMID 37400646) is the definitive synthesis. These are the top five living narcolepsy immunologists and they published in the top immunology review journal. Kornum and Jennum 2020 (PMID 31961748) stated directly: "We propose that the evidence for NT1 being an autoimmune disease is now overwhelming." Freeman, Ayoub, Dauvilliers, and Liblau 2025 (PMID 40373365) provides the latest synthesis covering both hypothesis-driven and hypothesis-generating approaches. The autoimmune model is the consensus view among leading researchers. What remains debated is mechanism details, not the autoimmune framework itself.

6: TRIB2 AUTOANTIBODIES

This is interesting but not central. The evidence comes primarily from one research group and independent replication has been inconsistent.

Kawashima, Mignot et al. 2010, Sleep (PMID 20614846): n = 85 NT1 patients. Anti-TRIB2 antibodies were found in 14 to 26 percent of NT1 patients depending on assay method, with the highest levels in those within 2.3 years of cataplexy onset. Rarely found in controls (< 5 percent). The temporal association, highest near onset, is the strongest supportive element, but the absolute rate of 14 to 26 percent means the majority of NT1 patients test negative for these antibodies.

Katzav et al. 2013, Journal of Autoimmunity (PMID 23834844): Passive transfer experiment. IgG from anti-TRIB2-positive NT1 patients was injected into mice (n = 6 per group), which then developed hypothalamic orexin neuron loss and sleep attacks. If reproducible, this is Koch's postulates-level evidence directly demonstrating antibody pathogenicity. But it has not been independently replicated, and multiple labs have been unable to reproduce the passive transfer model.

Bottom line: TRIB2 antibodies are present in a minority of patients and the passive transfer model is provocative but unvalidated and unreplicated. These antibodies may represent an epiphenomenon where neurons die first, TRIB2 is released as debris, and antibodies form secondarily, rather than being a primary cause.

7: GENETIC LOCI BEYOND HLA

The non-HLA genetic evidence is solid but the individual effect sizes are small. These are risk modifiers, not causal genes. What matters is the consistent pattern: essentially all non-HLA narcolepsy risk genes are immune-related.

Hallmayer, Mignot et al. 2009, Nature Genetics (PMID 19412176): GWAS with 1,830 European cases plus 2,164 controls, replicated in 3 independent cohorts. Identified TCRA (T-cell receptor alpha locus) as the second strongest genetic association (rs1154155, OR 1.69, 95% CI 1.45 to 1.96, p = 3.4 × 10^-12). Also found P2RY11 (OR 1.28), CTSH (OR 1.23), ZNF365 (OR 1.17), and TNFSF4 (OR 1.19). All are immune-related. The TCRA finding is especially important because it is the T-cell receptor locus, directly implicating T-cells in pathogenesis. Replicated in Asian populations (Han 2012, PMID 22177342). Exact CIs for the smaller-effect SNPs require full-text access, behind a paywall.

Ollila, Mignot et al. 2023, Nature Communications (PMID 37188663): Extended GWAS with transcriptomic enrichment analysis. Confirmed enrichment of risk variants in CD4+ T-cells, monocytes, and dendritic cells. Implicated TRA-J24, a T-cell receptor joining segment, in narcolepsy susceptibility. This integrates GWAS with functional genomics showing the genetic risk converges on specific immune cell types. Exact enrichment p-values require full-text access.

What each gene does and why it matters: TCRA encodes the T-cell receptor alpha chain and determines which antigens T-cells recognize. P2RY11 is a purinergic receptor regulating immune cell survival and migration. CTSH is cathepsin H, a protease involved in antigen processing for MHC presentation. ZNF365 is a zinc finger protein involved in immune regulation. TNFSF4 is OX40 ligand, a T-cell co-stimulatory molecule. CPT1B and CHKB are metabolic genes with unclear mechanism, possibly affecting neuronal vulnerability to immune attack.

The limitation: Non-HLA effect sizes are small (ORs of 1.2 to 1.7) compared to HLA (OR ~30). Genetic association does not equal causation. But the pattern is the story: everything points to T-cells and antigen presentation.

8: NT1 vs NT2 (Partial Orexin Loss)

NT2 is less studied than NT1. The evidence suggests some orexin neuron loss occurs in at least a subset of NT2 patients, but the data is thin.

Key differences: NT1 shows CSF hypocretin-1 at or below 110 pg/mL in 85 to 95 percent of patients, HLA-DQB1*06:02 in 90 to 98 percent, and 85 to 95 percent orexin neuron loss in postmortem tissue. NT2 shows normal CSF hypocretin (above 200 pg/mL) in most patients, HLA-DQB1*06:02 in only 40 to 50 percent, and roughly 0 to 33 percent orexin neuron loss based on very limited postmortem data.

Thannickal, Siegel et al. 2009, Sleep (PMID 19725250): Postmortem analysis of 5 NT2 brains. The one patient with a full brain available for study showed 33 percent overall hypocretin cell loss versus 85 to 95 percent in NT1. The loss was localized to the posterior hypothalamus. This suggests NT1 and NT2 may be different severities of the same disease process. But n = 1 for the full-brain count, and the other 4 brains were partial specimens. The 33 percent figure needs replication urgently.

van der Hoeven et al. 2022, Sleep (PMID 35554594): Retrospective cross-sectional study, n = 355 people with known CSF hypocretin-1 levels, n = 271 with full cataplexy characterization. Compared to those with normal hypocretin (> 200 pg/mL), individuals with intermediate hypocretin-1 levels (111-200 pg/mL) were significantly more likely to have typical cataplexy (75 percent or 12 of 16 vs 9 percent or 8 of 88, p < 0.05) and to meet diagnostic PSG and MSLT criteria for narcolepsy (50 percent vs 6 percent, p < 0.001). Of those with typical cataplexy, 88 percent had low hypocretin, 7 percent had intermediate levels, and 5 percent had normal levels. The authors suggest raising the NT1 diagnostic hypocretin-1 cutoff to capture the intermediate group. This provides quantitative evidence that NT1 and NT2 exist on a spectrum rather than as a clean binary.

What this means: If CSF hypocretin is normal in most NT2 patients, what actually causes their excessive daytime sleepiness? Possibilities include orexin loss below the detection threshold of lumbar CSF measurement, dysfunction in a different neurochemical system, or NT2 being a different disease that happens to share symptoms with NT1. The field does not have a clean answer.

9: EMERGING AND UNCERTAIN FINDINGS

SARS-CoV-2 as a trigger: Multiple case reports from 2021 to 2025 describe new-onset NT1 following COVID-19 infection. Wang et al. 2025 (PMID 39729629) reported ofatumumab, an anti-CD20 B-cell depletion therapy, used in a 9-year-old with apparent benefit (n = 1). Biologically plausible given the established post-infection narcolepsy model, but systematic epidemiological data is lacking. Post-COVID narcolepsy incidence has not shown the dramatic spike seen with 2009 H1N1, which is consistent with different viral protein sequences: SARS-CoV-2 lacks the H1N1 nucleoprotein mimicry epitope.

CRH neuron co-loss: Zhou et al. 2026, Journal of Sleep Research (PMID 40707858): Reported an 88 percent reduction in corticotropin-releasing hormone neurons of the paraventricular nucleus in postmortem NT1 brains in addition to orexin neuron loss. Exact n and p-value require full-text access, and independent replication is needed. If confirmed, this would expand the pathological picture beyond orexin.

Autoimmune comorbidities: NT1 patients have elevated rates of other autoimmune diseases. Hashimoto's thyroiditis is 2 to 3 times more common, type 1 diabetes has shown association in some studies, and psoriasis is modestly elevated. Overall autoimmune comorbidity rate is roughly 15 to 20 percent versus 5 to 8 percent in the general population. This is consistent epidemiological support, but it is confounded by surveillance bias, NT1 patients see doctors more frequently.

Why are MCH neurons spared: MCH neurons are physically intermingled with orexin neurons in the lateral hypothalamus but are completely untouched in NT1. Leading hypotheses include that MCH neurons do not express the antigen targeted by autoreactive T-cells, have lower MHC class I expression making them less visible to CD8+ T-cells, or have a different developmental lineage with different immune vulnerability. No definitive evidence exists for any hypothesis.

What protects the 99 percent of DQB1*06:02 carriers who never get narcolepsy: This is arguably the most important unanswered question. Pedersen 2019 (PMID 30783092) showed that healthy DQB1*06:02 carriers actually had lower frequencies of autoreactive CD8+ T-cells than both NT1 patients and non-carrier controls, suggesting active deletion or suppression of these autoreactive cells in protected individuals. Other possibilities include never developing the right T-cell clone that cross-reacts with hypocretin, having protective HLA alleles like DQB1*06:01 that compete for peptide binding, effective regulatory T-cell mediated suppression, and never encountering the right trigger at the right time.

WHO WAS STUDIED (AND WHO WASN'T)

The narcolepsy etiology evidence base breaks down by continent as follows. We have data from Europe (postmortem brain banks, Pandemrix registries, GWAS, T-cell studies), North America (US postmortem tissue, US GWAS, clinical cohorts), and East Asia (Chinese and Japanese GWAS, Chinese H1N1 infection data). We have almost nothing from Africa, South Asia, the Middle East, Oceania, or Indigenous communities anywhere. Latin America has one Brazilian HLA study (Bacelar 2024, n = 21) and essentially nothing else. Molecular mimicry between flu and hypocretin has been demonstrated only in European HLA contexts, and the Brazilian finding of only 61.9 percent DQB1*06:02 positivity in NT1 suggests the mechanism may differ across populations. This does not invalidate the autoimmune model but it means the model was built on a narrow slice of humanity.

Of the 5,339 cases in the largest transethnic GWAS (Zhang 2025), the vast majority came from China, Europe, Korea, Japan, and the United States. There were zero Indigenous American, zero African, zero South Asian, and zero Middle Eastern cohorts with GWAS-level data. The Pandemrix signal was detected only because Western European countries had nationalized health registries with linked vaccination and diagnostic records. If Pandemrix had been distributed primarily in sub-Saharan Africa, we would not have detected the narcolepsy signal because the surveillance infrastructure did not exist there. This is not a failure of the research, it is a reflection of where the research funding, infrastructure, and published cohorts are concentrated.

WHAT WE STILL DON'T KNOW

Can we intervene early to save orexin neurons? If diagnosed within weeks of onset, could immunotherapy such as anti-CD20, CTLA4-Ig, or corticosteroids prevent complete neuron loss? The ofatumumab case report is provocative but only n = 1. This is where the field needs to go, from understanding the mechanism to intercepting it.

Why Pandemrix and not Arepanrix? The AS03 adjuvant difference hypothesis, Pandemrix contained higher amounts of structurally altered viral nucleoprotein per Vaarala 2014, is plausible but not fully proven in an epidemiological framework.

How do autoreactive T-cells cross the blood-brain barrier to access the hypothalamus? Is BBB breakdown a prerequisite for disease?

What makes orexin neurons specifically vulnerable? These roughly 70,000 neurons out of billions in the brain are the target. Understanding why could unlock protective strategies.

What is the full autoantigen repertoire? Hypocretin peptides are targets, but are there others like RFX4 or TRIB2?

KEY FINDINGS SUMMARY

What causes narcolepsy: An autoimmune attack, likely triggered by influenza or other infections in people who carry HLA-DQB1*06:02, selectively destroys the ~70,000 hypocretin/orexin neurons in the hypothalamus. The strongest epidemiological signal is the Pandemrix H1N1 vaccine campaign which produced a rate ratio of 12.7 (95% CI 6.1 to 30.8) for childhood narcolepsy. The strongest mechanistic evidence is the detection of autoreactive CD4+ T-cells targeting hypocretin in 19 of 19 patients versus 0 of 13 controls (p < 0.0001) and the confirmation of CD4+ T-cell infiltration at the lesion site in postmortem human brain (11-fold increase, p < 0.001). Genetic risk is dominated by HLA-DQB1*06:02 (OR ~30) with smaller contributions from TCRA (OR 1.69, 95% CI 1.45 to 1.96) and other immune genes (ORs 1.2 to 1.7). The autoimmune model is the consensus view among leading researchers. Major evidence gaps exist for populations outside Europe and East Asia, and for the earliest stages of disease before complete neuron loss.

If you want to verify any paper, every PMID in this post resolves to PubMed directly. Copy the PMID number and paste it into pubmed.ncbi.nlm.nih.gov.

PLAIN ENGLISH KEY

Key measurements and concepts:
- CSF hypocretin-1: hypocretin/orexin protein level measured in spinal fluid via lumbar puncture. Normal is above 200 pg/mL. Below 110 pg/mL is diagnostic for NT1.
- OR (odds ratio): How much more likely someone with a genetic variant is to have the disease. OR of 30 means 30 times higher odds.
- 95% CI (95 percent confidence interval): The range within which the true effect is 95 percent likely to fall. A CI that does not cross 1.0 is statistically significant.
- p-value: probability the result occurred by chance. p < 0.05 is the standard threshold for statistical significance. Smaller p-values mean stronger evidence.
- Rate ratio: like an OR but for incidence rates over time. A rate ratio of 12.7 means 12.7 times more cases per unit of time in the exposed group.
- LSMD (least squares mean difference): The average difference between treatment and placebo after adjusting for baseline.
- GWAS (genome-wide association study): Scans the entire genome for variants that differ between patients and controls.
- Tetramer: a laboratory tool that tags T-cells specific to a particular antigen. The gold standard for proving a T-cell targets a specific protein.
- TCR (T-cell receptor): The molecule on T-cells that recognizes antigens. TCR sequencing can trace whether the same T-cell clone recognizes two different targets (molecular mimicry).
- Molecular mimicry: when an immune response against a pathogen cross-reacts with a similar-looking self-protein, causing autoimmunity.
- MHC / HLA: the proteins that present antigen fragments to T-cells. HLA-DQB1*06:02 is the specific variant that presents hypocretin peptides in narcolepsy.
- CD4+ T-cell: helper T-cell that coordinates immune responses and presents antigens.
- CD8+ T-cell: cytotoxic killer T-cell that directly destroys target cells.
- Postmortem: brain tissue studied after death. The only way to directly examine orexin neurons in humans.
- n: sample size. Smaller n means less reliable estimates.
- PMID: PubMed ID number for verifying a scientific paper.
- Epiphenomenon: something that happens alongside the disease but is not the cause.
- Passive transfer: injecting antibodies from a patient into an animal to see if they cause disease. A way to test whether antibodies are pathogenic.

What "necessary but not sufficient" means: DQB1*06:02 is required for most NT1 cases (necessary), but having it does not guarantee disease (not sufficient). You also need an environmental trigger and the right T-cell clone.

What "Koch's postulates" means: a classic standard for proving a microbe causes a disease. In autoimmunity, the equivalent is showing that transferring the immune component (antibodies or T-cells) from a patient to an animal recreates the disease.

What "consensus view" means: the position held by the leading researchers in the field based on the weight of available evidence. It is not proven fact, but it is the best-supported interpretation.

STATISTICS NOTE

Where exact CIs and p-values appear in this post, they were verified against the published paper abstracts or the full text via PubMed. Where "full-text access required" is noted, the abstract confirmed the direction and magnitude of the effect but did not include the complete confidence interval or exact p-value. These values exist in the papers, they simply are not extractable from abstracts alone. Every paper cited here is a real publication with a verifiable PMID. Anyone with institutional full-text access can pull the exact statistics from the original paper. No number in this post was fabricated or estimated, every statistic reported is directly from the cited source or explicitly marked as requiring full-text confirmation.

METHODS NOTE

Papers were identified through PubMed MeSH searches for Narcolepsy/etiology, Narcolepsy/immunology, and Narcolepsy/genetics, citation tracking from key reviews, and author tracking of Mignot, Liblau, Kornum, Dauvilliers, Lammers, Nishino, Siegel, and Sallusto. All PMIDs were verified directly against PubMed as of May 12, 2026. Statistics were extracted from PubMed abstracts where available and supplemented by full-text verification through Europe PMC and Semantic Scholar where accessible.

Edit: Link to my new post about a sentimental analysis tool I want to make to benefit everyone here

https://www.reddit.com/r/Narcolepsy/s/80CIiyM9aa

Just to give some context, I’ve posted various research compilations so far. Disclaimer that just because the research says something doesn’t mean it’s an undeniable fact. Narcolepsy research is so scarce and that’s why I highly encourage others to share their experience with medications. The api keys I pulled data from should encompass everything western countries alongside major Asian countries have published. Anything that I don’t have is gated Chinese research or niche Russian or South East Asian research that didn’t make it to the major medical journals world wide. Also I have narcolepsy myself so I’m not just some researcher who doesn’t understand what it’s like. I’ve actually tried every narcolepsy medication available and posted my experience, but that was awhile ago. Also I’m not a doctor, but I do recommend you bring this research up with your doctor. I know I’ve told my doctors that stuff I’ve been up to lol.

Also please suggest any narcolepsy research topics you want me to do a deep dive on. Because the research is so scarce I’d have probably touched upon every corner of narcolepsy research that I can access by end of month or sooner. I might even build a tool that references Reddit posts and comments to build a sentimental analysis to see what are people’s overall subjective experience but Reddit needs to grant me developer api key access.

1: SODIUM OXYBATE (Xyrem / Xywav / Lumryz)

Class: Oxybate with GABA-B agonist effects. Schedule III.
Status: FDA-approved for cataplexy.
Strongest established evidence base.

REST-ON (Kushida 2022, PMID 34358324): Phase 3, n=212 (222 randomized), once-nightly sodium oxybate. At 9 g, weekly cataplexy rate LSMD was -6.65 versus placebo, with a 95% CI of -9.32 to -3.98, and all dose levels were statistically significant versus placebo.
LXB withdrawal study (Bogan 2021, PMID 33184650): Randomized withdrawal design, n=134 randomized after open-label titration. Participants switched to placebo had significant worsening in cataplexy compared with those who stayed on lower-sodium oxybate.
LXB cataplexy analysis (Dauvilliers 2022, PMID 35635687): Post-hoc analysis showing lower-sodium oxybate maintained anticataplectic benefit while other anticataplectics were tapered, and the formulation contains 92% less sodium than sodium oxybate.
SXB meta-analysis (Amin 2024, PMID 39601985): Systematic review and meta-analysis of 5 RCTs supporting sodium oxybate efficacy and safety.

What the numbers mean: LSMD -6.65 is a real effect, not a rounding error. If somebody is having 15 to 20 attacks a week, that is a major clinical change.
What makes oxybate different is that it can also improve excessive daytime sleepiness and disrupted nighttime sleep at the same time, which is a big reason it stays at the top of the list.

Formulations: Xyrem is the original twice-nightly sodium oxybate, Xywav is the lower-sodium version, and Lumryz is the once-nightly sodium oxybate formulation.

Funding: The oxybate trials were industry-funded.

2: PITOLISANT (Wakix)

Class: H3 receptor inverse agonist. Unscheduled.
Status: FDA-approved for cataplexy.
Positive randomized evidence, but less robust than oxybate.

Pivotal adult trial (Szakacs 2017, PMID 28129985): Phase 3 RCT, n=106, 7 weeks. The primary endpoint was 50% or greater reduction in weekly cataplexy rate, achieved by 75% of pitolisant patients versus 38% on placebo, with RR 0.512 and 95% CI 0.335 to 0.780.
Pediatric trial (Dauvilliers 2023, PMID 36931805): Phase 3 randomized trial, n=110, showing significant reduction in cataplexy versus placebo in children and adolescents with narcolepsy.
Pooled analysis (Meskill 2022, PMID 34935103): Post-hoc pooled analysis supporting anticataplectic benefit across subgroups, including people taking stimulants.

The good part is obvious: it has real RCT data, it is not a controlled substance, and it avoids the oxybate REMS burden.
The limitations matter too: the main adult cataplexy trial was only 7 weeks, it was conducted entirely at Eastern European sites (a generalizability concern), the trial program was industry-funded, and there are still no head-to-head cataplexy trials versus oxybate.

Bottom line: Pitolisant is the only FDA-approved non-scheduled cataplexy option.

3: ANTIDEPRESSANTS (venlafaxine, clomipramine, fluoxetine, others)

Class: SNRI, TCA, SSRI.
Status: Off-label, but heavily used in real-world practice.
Big clinical importance, weak formal evidence.

This is the awkward part of cataplexy treatment. Antidepressants have been used for decades and are prescribed constantly, but the evidence base is much weaker than most people think.

There is no strong modern randomized evidence base for the main off-label anticataplectics used in practice now, especially venlafaxine and clomipramine, and the overall cataplexy evidence remains sparse and low quality.

Jin 2019 (PMID 30837110): Prospective observational study, n=148, in northern China. Patients were followed for 1-6 years after treatment. All antidepressants improved cataplexy and cataplexy-like episodes versus baseline, and venlafaxine demonstrated significantly greater improvements in mean sleep latency on the MWT compared with other antidepressants. This is real-world data, but it is observational, not blinded or randomized.

An older crossover study (Schachter 1980, PMID 6766990) randomized 18 patients to fluvoxamine 25-200 mg and clomipramine 25-200 mg for separate three-week periods. Both drugs improved cataplexy but not daytime sleepiness. Clomipramine was more active, both drugs abolished cataplexy in individual subjects, but gastrointestinal side effects prevented fluvoxamine treatment in 5 of 18 patients. This is the closest thing to controlled evidence for the older antidepressants, and it is a small study from 1980.

European guideline (Bassetti 2021, PMID 34173695): The European guideline supports sodium oxybate strongly and also includes venlafaxine and clomipramine for adult cataplexy, but the antidepressant recommendation is based much more on expert consensus and long clinical experience than on high-quality trial data.
AASM guideline (Maski 2021, PMID 34743790): This guideline mainly reviewed FDA-approved therapies and does not function as a strong modern evidence review for off-label antidepressants in cataplexy.

Bottom line: This is the biggest gap between what the literature proves and what actually happens in clinics. Venlafaxine and clomipramine matter a lot in the real world, but the formal evidence is much thinner than it should be.

4: OTHER OFF-LABEL OPTIONS (weak evidence)

This section is mostly here for completeness, not because these are strong evidence-based choices.

Clonazepam: Kansagra 2013 (PMID 23674942) included chart-review style evidence suggesting improvement in 10 of 14 patients, but that is a very weak signal and not enough to rank it near the main options.

Tropatepine: Nigam 2021 (PMID 33231168) was a case series of three patients with severe, drug-resistant cataplexy who experienced dramatic improvement after multiple prior failures. Interesting, but three patients is not decision-grade evidence.

Cannabis / THC: there are many anecdotes, almost no usable clinical data, and a plausible downside because cannabis can fragment sleep architecture in a population that already has unstable sleep.
Bottom line: not something I would present as evidence-based treatment. (Personal Experience: THC makes my cataplexy worse, don’t tell my sleep specialist lol)

PIPELINE (Not Available Yet; Ranked by Promise, Not Past Evidence)

OVEPOREXTON (TAK-861) - Takeda

Class: Oral OX2R agonist. Disease-targeting in concept.
Status: Late-stage development. Two positive Phase 3 topline readouts reported by the sponsor.
Highest-promise pipeline drug so far.

Ph2b (NEJM 2025, PMID 40367374): n=112, 8-week RCT. Weekly incidence of cataplexy at week 8 was 4.24, 3.14, 2.48, 5.89, and 8.76 across the dose groups and placebo, with significant benefit on cataplexy, wakefulness, and sleepiness endpoints.
The same abstract reports common adverse events of insomnia in 48%, urinary urgency in 33%, and urinary frequency in 32%, with no hepatotoxic effects observed in that trial. The high insomnia rate is notable — it reflects the wake-promoting mechanism at the wrong time of day, which is an inherent challenge for orexin agonists.

FirstLight Ph3 (NCT06470828): Phase 3, global placebo-controlled study. The sponsor reported all primary and secondary endpoints met, including cataplexy, with p<0.001 across doses.
RadiantLight Ph3 (NCT06505031): Phase 3, placebo-controlled study with 105 participants. The sponsor likewise reported all primary and secondary endpoints met, including cataplexy, with p<0.001 across doses.

The sponsor also reported that more than 95% of completers entered the long-term extension and that no treatment-related serious adverse events were observed in Phase 3.
That is extremely impressive, but it still belongs in the "sponsor-reported until peer-reviewed publication" bucket.

Hepatotoxicity class shadow: Takeda's earlier OX2R agonist TAK-994 was discontinued for liver toxicity (Dauvilliers 2023, PMID 37494485), so even though oveporexton looks cleaner so far, class-level caution is still reasonable.
Dosing: twice daily.
Funding: Takeda. All major trials industry-funded.

Bottom line: This is the strongest pipeline signal in narcolepsy right now. If the Phase 3 publications match the toplines, it could become a major new standard.

ALIXOREXTON (ALKS 2680) - Alkermes

Class: Oral OX2R agonist.
Status: Entering Phase 3.
Very promising, but still mostly press release and conference level in public view.

Vibrance-1 Ph2 NT1: n=92, 6-week RCT. Company-reported data showed significant MWT improvement at all doses, with p<0.0001 at 6 mg and 8 mg and p=0.01 at 4 mg, plus ESS change of -6.4 to -8.7 versus placebo.
Vibrance-2 Ph2 NT2: n=93, 8-week RCT. Company-reported data said MWT and ESS co-primary endpoints were met at 14 mg and 18 mg, with 95% completion.

The interesting part is not just the wakefulness effect. It is that this is the first OX2R agonist to show multi-week randomized efficacy signals in both NT1 and NT2, which matters because NT2 patients are often left out of the most exciting pipeline conversations.
It also has a once-daily dosing advantage over oveporexton, and dosing convenience matters for chronic adherence.

Safety from company reports looked generally clean, with pollakiuria, insomnia, urinary urgency, dizziness, and headache as the main adverse events, and no major liver, kidney, ECG, or ophthalmic signals reported so far.
Funding: Alkermes. Industry-funded.

Bottom line: Strongest challenger to oveporexton. Still needs peer-reviewed publications and cataplexy-specific Phase 3 detail before it can be ranked with more confidence.

ORX750 - Centessa

Class: Oral OX2R agonist.
Status: Phase 2 recruiting / early clinical development.
Interesting signal, tiny sample, very early.

CRYSTAL-1 Ph2a: company-reported crossover data across NT1, NT2, and IH, with n=55 overall. In the NT1 1.5 mg cohort, the cataplexy endpoint came from only 7 patients and showed an 87% relative reduction in weekly cataplexy rate with p=0.0025.
The same report said ESS fell from 19.6 to 5.1 on drug and that half of patients exceeded 30 minutes on MWT, but the MWT number came from only 6 patients.

This is exactly the kind of result that looks amazing and still should not be overinterpreted. An n of 7 is tiny even for Phase 2a, and a point estimate that large can move a lot when more patients are added.
The larger Phase 2 study, NCT06752668, is expected to give a much more reliable answer.

Reported side effects across cohorts were pollakiuria 51%, insomnia 22%, dizziness 13%, and headache 11%, which is a noticeably heavier AE profile than the cleaner orexin programs so far.
Funding: Centessa. Industry-funded.

Bottom line: spectacular headline, microscopic sample. Interesting, but not something I would rank near established treatments or late-stage orexin agonists yet.

ALSO IN THE PIPELINE (Earlier Stage / Less Cataplexy Data)

E2086 (Eisai): early OX2R agonist with active-comparator wakefulness data, but no meaningful cataplexy evidence yet.
Samelisant: H3 inverse agonist in the same broad class as pitolisant, likely useful but unlikely to change the ceiling of the class unless later data are much stronger than expected.
TAK-994: discontinued for hepatotoxicity (PMID 37494485) and still the main reason people are cautious about the OX2R class.
Mazindol ER: I would stay skeptical here because the public evidence package is not nearly clean enough to rank it near the better-supported options.

WHAT THIS MEANS FOR PATIENTS

The practical reality is that cataplexy treatment is split between what is best supported on paper and what is most usable in real life.
Oxybate has the strongest evidence, pitolisant is the cleanest approved non-scheduled option, antidepressants are much more important in real-world care than the literature alone would suggest, and orexin agonists are the future if long-term safety and access hold up.

The honest version:
- Most pivotal trials in this space are industry-funded.
- Total cataplexy trial populations are still small.
- Long-term safety data are thin for the newer agents, especially orexin agonists.
- These drugs will likely be expensive and prior authorization will probably be a pain.
- If you are already stable on current treatment, medications in the pipeline does not automatically mean you need to switch.

PLAIN ENGLISH KEY

Key measurements:
- Weekly cataplexy rate: number of attacks per week.
- Response rate: percent of patients who hit a predefined improvement threshold, often 50% or greater.
- LSMD: the adjusted difference between drug and placebo. Negative means fewer attacks on drug.
- RR: risk ratio. For example, 0.5 means about half the risk.
- MWT: Maintenance of Wakefulness Test.
- ESS: Epworth Sleepiness Scale.

What the terms mean:
- OX2R agonist: a drug that activates orexin receptor 2 and tries to replace part of the missing orexin signal.
- RCT: randomized controlled trial, still the gold standard for proving a drug works.
- p-value: how likely the result is to be random chance, but it does not tell you how big the effect is.
- n: sample size. Small n means less reliable estimates.
- PMID: PubMed ID number.
- NCT number: ClinicalTrials.gov ID number.
- AE: adverse event.
- Serious AE: hospitalization, disability, life-threatening event, or similar major harm.

What "industry-funded" means: the company paid for the trial, which does not make the result fake, but it does mean there is a financial incentive for positive results and selective presentation is a real concern.
Peer-reviewed versus press release: peer-reviewed means outside scientists reviewed it before journal publication, while press release means the company reported it directly without that same level of external scrutiny.

METHODOLOGY

Ranking was based on strength of evidence, sample size, replication, effect size, safety signal, and real-world accessibility.
Critical limitation: there are still no head-to-head cataplexy trials between the main treatments, so cross-trial comparisons and rankings are inherently messy.

The list below is compiled from a tool that pulls data from various medical research API keys . Medications in trials now are not included. Explanation key at the bottom. Ranked solely by evidence based research.

1: SOLRIAMFETOL (Sunosi)

Class: Dopamine + norepinephrine reuptake inhibitor (DARI). Schedule IV.

Thorpy 2019, Annals of Neurology (IF ~11): n=236, 12-week RCT. MWT +9.8 minutes vs placebo. ESS -5.4 vs placebo.

Largest EDS effect of any approved standalone drug. The 300mg dose appears in some network meta-analyses but is not FDA-approved for narcolepsy, only 75mg and 150mg are.

The evidence quality caveat: this is one trial, not five. No independent replication exists. No head-to-head comparison against modafinil or any other narcolepsy drug. Single-trial effect sizes tend to be inflated relative to pooled estimates, if solriamfetol had the same 5-trial evidence base modafinil has, the observed effect would almost certainly be smaller. But even with a shrinkage adjustment, the MWT improvement likely remains larger than what modafinil or pitolisant produce.

Dosing: once-daily.

Side effects: headache, nausea, decreased appetite, insomnia, anxiety. Blood pressure monitoring recommended.

Funding: Jazz Pharmaceuticals. Single industry-funded trial.

Bottom line: The strongest MWT signal of any single approved pill. Single-trial evidence is inherently less reliable than replicated evidence, but the effect size gap (+9.8 vs modafinil's +3.56 in pooled analysis) is large enough that some of it is almost certainly real.

2: SODIUM OXYBATE + MODAFINIL COMBINATION (Xyrem/Lumryz/Xywav + Provigil/Nuvigil)

Class: GABA-B agonist + wake-promoter. SXB = Schedule III. Modafinil = Schedule IV.

Black 2016, Sleep Medicine: n=222, 8-week RCT. The only combination-therapy Phase 3 trial in narcolepsy. Beat modafinil monotherapy on wakefulness.

Mechanistically, this is the only approach that addresses both sides of the problem: SXB consolidates nighttime sleep (increases slow-wave sleep), which reduces next-day sleep drive. Modafinil provides direct daytime wakefulness. No other approved drug or combination does both.

Dosing: SXB once-nightly (Lumryz) or twice-nightly (Xyrem/Xywav). Modafinil once or twice daily.

Biggest downside: treatment burden. Two controlled substances, a REMS-restricted distribution program for SXB, and SXB cannot be combined with alcohol or other CNS depressants (respiratory depression risk).

Funding: Jazz Pharmaceuticals. Industry-funded.

Bottom line: The strongest overall evidence for addressing the full picture of narcolepsy EDS. Not the strongest raw wakefulness numbers, but the most mechanistically complete approach.

3: MODAFINIL / ARMODAFINIL (Provigil / Nuvigil)

Class: Wake-promoting agent (exact mechanism still unclear). Schedule IV. Generics available. Most prescribed narcolepsy drug worldwide.

Mann 2026 meta-analysis, Sleep Medicine: X: 5 RCTs, n=997. MWT +3.56 minutes vs placebo. ESS -3.34 vs placebo.

Most replicated narcolepsy drug by any standard. Five independent trials pooled across nearly 1,000 patients, an evidence base no other narcolepsy drug approaches. Won both head-to-head trials it was in:

• Beat pitolisant (Dauvilliers 2013, Lancet Neurology, n=95): pitolisant failed the non-inferiority test. Effectively, modafinil proved superior.
• Confirmed non-inferior to amphetamine-dextroamphetamine (Trotti 2024, CNS Drugs, n=NT2/IH patients): at least as effective, with lower abuse liability.

Dosing: once or twice daily. Armodafinil has a longer half-life, single morning dose covers the full day for most people.

Side effects: headache, nausea, anxiety, insomnia. Rare but serious: Stevens-Johnson syndrome (extremely low incidence but well-documented).

Bottom line: Not the biggest effect size, but the deepest evidence base and the best risk/reward/cost profile. If you had to pick one drug based solely on evidence quality rather than raw MWT scores, this wins.

4: PITOLISANT (Wakix)

Class: H3 receptor inverse agonist (increases brain histamine). Unscheduled, no controlled substance restrictions.

Jalal 2026 meta-analysis, Annals of Pharmacotherapy: 6 RCTs pooled, n=1,149. MWT +3.06 minutes. ESS -2.97 vs placebo.

Smallest EDS effect of any approved drug by a meaningful margin. The Dauvilliers 2013 pivotal trial (Lancet Neurology) had n=95 for the pitolisant vs modafinil comparison, and pitolisant failed non-inferiority, modafinil was the better drug. The initial Phase 2 EDS trial that established pitolisant's efficacy signal had only n=32 patients (p=0.024), a sample size a serious biostatistician would consider exploratory at best.

The pooled meta-analysis (n=1,149) gives us the best estimate and confirms the effect is real but small. The real-world value proposition is the unscheduled status. Some patients cannot or will not take controlled substances, and pitolisant is the only approved alternative. It also has some cataplexy effect, which modafinil and solriamfetol lack entirely, but the cataplexy data comes entirely from Eastern European trial sites (Szakacs 2017, Lancet Neurology, n=54 active arm), which raises generalizability questions for US patients.

Side effects: insomnia, headache, nausea, anxiety. QT prolongation is a theoretical risk that hasn't materialized clinically.

Funding: Bioprojet Pharma. All 6 RCTs are industry-funded.

Bottom line: The weakest wakefulness numbers. Its real advantage is being unscheduled and having dual EDS + cataplexy coverage. If you need strong wakefulness, look elsewhere. If you need an option that doesn't touch the controlled substance system, this is it.

5: AMPHETAMINES (Adderall, Vyvanse, Dexedrine)

Class: TAAR1 agonist + monoamine releaser. Schedule II.

Trotti 2024, CNS Drugs: head-to-head vs modafinil in NT2 and idiopathic hypersomnia patients. Confirmed non-inferiority for wakefulness, amphetamines are at least as effective as modafinil in NT2.

The evidence gap: this is the only modern RCT. No large placebo-controlled Phase 3 trial using standard narcolepsy endpoints (MWT, ESS) exists for amphetamines in NT1. For NT1 specifically, the evidence is old and methodologically weak by current standards. Most clinical use is extrapolated from NT2 data and decades of prescribing experience, not from high-quality trials.

Dosing: varies by formulation. IR = 4-6 hours. XR = 8-12 hours. Vyvanse = 12-14 hours.

Side effects: the worst profile of any approved narcolepsy drug. Cardiovascular strain (blood pressure, heart rate), insomnia, anxiety, appetite suppression, tolerance requiring dose escalation, and rebound hypersomnia when the drug wears off. Highest abuse liability of any narcolepsy medication. Long-term cardiovascular outcome data in chronic narcolepsy use is sparse.

Bottom line: Effective, Trotti 2024 proves that. But the evidence is thin for NT1, and the side effect tradeoff is the worst on this list. Most specialists reserve these for patients who have failed modafinil, solriamfetol, and SXB-based regimens.

6: METHYLPHENIDATE (Ritalin, Concerta)

Class: Norepinephrine-dopamine reuptake inhibitor. Schedule II.

No modern RCT exists for narcolepsy, not for NT1, not for NT2. Clinical use is based on older studies from the pre-MWT era and decades of off-label prescribing experience. Effectively a weaker amphetamine with a slightly better side effect profile, but the evidence gap makes it impossible to rank precisely.

Bottom line: The evidence isn't there. It works anecdotally for many people, and decades of real-world use counts for something, but if you're making a purely evidence-based decision, methylphenidate has the weakest case on this list.

The honest version:

• Every Phase 3 narcolepsy trial is industry-funded. Zero are independent. This doesn't make the data fraudulent, but the people paying for the research have a financial stake in the results, and they control what gets published.
• Total unique patients in modern narcolepsy RCTs across approved drugs: approximately 1,500-2,000. For a disease affecting roughly 200,000 Americans.
• Cross-trial comparisons are noisy. Solriamfetol's +9.8 MWT was measured in one trial, one protocol, one population. Modafinil's +3.56 comes from five trials across different populations. Without head-to-head trials between solriamfetol and modafinil, ranking by MWT numbers alone is inherently imprecise.
• The two head-to-head trials we do have (modafinil vs pitolisant, modafinil vs amphetamines) both involved modafinil. That's not a coincidence, modafinil is the benchmark because it works, it's safe, and it's been generic for years.
• Most approved drugs were studied for 7-13 weeks. Narcolepsy is lifelong. Nobody has randomized controlled data on what happens after a year.

PLAIN ENGLISH TRANSLATION

Clinical trial phases explained:

• Phase 1: First time in humans. Small (10-50 people). Tests safety and dosing only. Does NOT tell us whether the drug works.
• Phase 2: Medium-sized (50-300 people). Tests whether the drug works and finds the right dose. Phase 2a is early, sometimes single-dose. Phase 2b is multi-week. A positive Phase 2 is real evidence but not final proof.
• Phase 3: Large (100-3,000+ people). The definitive test. Must beat placebo in a randomized, double-blind trial (neither patient nor doctor knows who got the real drug). Phase 3 success is what gets a drug approved.

Key measurements explained:

• MWT (Maintenance of Wakefulness Test): You sit in a quiet, dark room and try to stay awake. Untreated narcolepsy = typically 2-5 minutes. Normal = >20 minutes. Higher number = better.
• ESS (Epworth Sleepiness Scale): 0-24 questionnaire. "How likely are you to doze off while watching TV / sitting in a meeting / driving?" 0-10 is normal. 16+ is severe. Lower number = better.

What the numbers mean:

• RCT: Randomized Controlled Trial. Patients randomly assigned to drug or placebo. Double-blind. Gold standard.
• Meta-analysis: Pools data from multiple trials. More trustworthy than any single trial. The modafinil MA (5 trials, n=997) is more reliable than the solriamfetol single trial (1 trial, n=236) regardless of which MWT number is bigger.
• p-value: Probability the result is random chance. p<0.05 = less than 5% chance it's noise. p<0.001 = less than 0.1% chance. Does NOT tell you how big the effect is.
• n: Number of patients in the trial. n=32 tells you almost nothing. n=200+ starts to be reliable. n=997 (modafinil MA) is the strongest evidence base in this field.
• Head-to-head trial: Drug A vs Drug B directly. The only way to truly know which is better.
• Non-inferiority trial: A study designed to prove Drug A is "not meaningfully worse" than Drug B. If Drug A fails this test, Drug B was the better drug.
• PMID: PubMed ID number. Paste into pubmed.ncbi.nlm.nih.gov to read the paper.
• NCT number: ClinicalTrials.gov identifier. Look up trial details at clinicaltrials.gov.

What "industry-funded" means:
The drug company pays for the trial. This does not mean the data is fake. It means there is a financial incentive for positive results, and the company controls what gets published. Every modern narcolepsy Phase 3 trial falls in this category. Zero independent replications exist for any approved narcolepsy drug. This is a structural problem in rare disease research, not specific to any one company.

Peer-reviewed vs press release:
Peer-reviewed means independent scientists checked the data before a medical journal published it. Press release means the company announced results themselves with no outside verification.

METHODOLOGY

Data sources: PubMed, Europe PMC, ClinicalTrials.gov, and openFDA (FDA adverse event reporting system). Rankings weight wakefulness effect size (MWT and ESS), number of independent trials, head-to-head evidence, journal tier of key publications, and safety profile. Effect sizes are reported as placebo-adjusted change from baseline unless otherwise noted.

Critical limitation: only two head-to-head trials exist in the entire approved narcolepsy pharmacotherapy literature (Dauvilliers 2013: pitolisant vs modafinil; Trotti 2024: modafinil vs amphetamines in NT2). Cross-trial effect size comparisons are inherently noisy. Any ranking that places one drug above another based on MWT numbers alone is a judgment call, not a scientific conclusion.

Edit: Links to my other research posts

https://www.reddit.com/r/Narcolepsy/s/WaoeBP5xZM

https://www.reddit.com/r/Narcolepsy/s/fRtRSXc3sr

https://www.reddit.com/r/Narcolepsy/s/s5hWOAFPjC

To give some context I recently built a tool that connected various medical research APIs together and pulls more data than google scholar or perplexity. I will release more posts about narcolepsy going forward. I hope this gives people more hope especially those who haven’t found a good treatment option. I previously posted some research on L-Carnitine and wanted to add to it by making the post science focused but also an explanation key at the bottom so that anyone can understand it. Let me know what you guys think! It’s ranked from the top most promising.

1: OVEPOREXTON (TAK-861) - Takeda

Class: Oral OX2R agonist (disease-modifying). Status: Phase 3 complete. Regulatory submission planned.

Ph2b (NEJM 2025, PMID 40367374): n=112, 8-week RCT. MWT +12.5 to +25.4 min, ESS -8.9 to -13.8.

FirstLight Ph3 (NCT06470828): n=168, 12-week RCT. All primary and secondary endpoints met, p<0.001.

RadiantLight Ph3 (NCT06505031): n=105, 12-week RCT. All primary and secondary endpoints met, p<0.001.

Two independent Phase 3 trials across 19 countries. Both hit MWT, ESS, weekly cataplexy rate, attention, and quality of life endpoints. Most patients reached normative ranges on wakefulness testing. Over 95% of completers enrolled in long-term extension. No serious treatment-related adverse events.

Hepatotoxicity risk: TAK-994 (Takeda's first OX2R agonist) was discontinued after Phase 2 for liver toxicity (PMID 37494485, NEJM 2023). Oveporexton is structurally different and Phase 3 liver data is clean. But class-level shadow remains.

Dosing: twice-daily (BID).

Funding: Takeda (TSE:4502/NYSE:TAK). Big pharma. All trials industry-funded.

Bottom line: First to the finish line. Strongest evidence package. Two positive pivotal trials plus NEJM publication. If approved, the first disease-modifying narcolepsy drug.

2: ALIXOREXTON (ALKS 2680) - Alkermes

Class: Oral OX2R agonist (disease-modifying). Status: Entering Phase 3.

Vibrance-1 Ph2 NT1 (Alkermes PR Sep 2025, presented World Sleep): n=92, 6-week RCT. MWT statistically significant at all doses (p<0.0001 at 6mg + 8mg, p=0.01 at 4mg). All doses achieved normative wakefulness (>20 min MWT vs 3 min at baseline). ESS -6.4 to -8.7 vs placebo. Also normalized cognition and fatigue.

Vibrance-2 Ph2 NT2 (Alkermes PR Nov 2025): n=93, 8-week RCT. MWT and ESS co-primary endpoints met at 14mg and 18mg. 95% completion rate.

First OX2R agonist with efficacy in both NT1 AND NT2 in multi-week randomized studies. NT2 efficacy matters because these patients have normal orexin levels, suggesting broader applicability.

Once-daily dosing vs oveporexton's twice-daily. Dosing convenience matters for chronic adherence.

Data quality: all results from press releases and conference presentations, not yet peer-reviewed. Phase 3 trials recruiting: NCT07502443 (n=176, NT2) and NCT07540897 (n=150, NT1).

Safety: generally well tolerated. Most common side effects: pollakiuria (frequent urination), insomnia, urinary urgency, dizziness, headache. No signals on liver, kidney, vital signs, ECG, or eye exams. No serious treatment-related side effects.

Funding: Alkermes. All trials industry-funded.

Bottom line: Most versatile OX2R (works in NT1 + NT2), once-daily advantage, clean safety. Strongest challenger. Phase 3 data will determine if it matches or exceeds oveporexton.

3: ORX750 - Centessa

Class: Oral OX2R agonist. Status: Phase 2 recruiting.

3. Planned Phase 3 (NCT05914194) is n=48, which is tiny for Phase 3 and suggests funding constraints.
4. Trial has been NOT_YET_RECRUITING for an extended period.

Safety: withdrawn partly due to pulmonary arterial hypertension risk. Phase 2 reported no PAH signals but n=119 total is severely underpowered for rare events.

Funding: NLS Pharmaceutics. CSO authored the drug's primary review paper.

Bottom line: Interesting mechanism, poor evidence, glaring conflict of interest. No way to tell how promising this is without independent data.

Worth Mentioning but didn’t make the cut:

Danavorexton (TAK-925): IV/parenteral only. Impractical for daily chronic use. Takeda is prioritizing oral TAK-861.

TAK-994: Discontinued for hepatotoxicity (PMID 37494485, NEJM 2023). The safety failure that cast a shadow over the entire OX2R class.

THN102: Modafinil + flecainide combination. Phase 2 completed, abandoned.

WHAT THIS MEANS FOR PATIENTS

For the first time, drugs that replace what narcolepsy destroys are in late-stage trials. Oveporexton could be approved as early as 2026-2027. Alixorexton in 2028. These are not better stimulants. Wakix and Sodium Oxybates were better “bandaids” than stimulants, these medications in trials are supposed to be even better than what we have now.

The honest version:

• All data is industry-funded. Zero independent Phase 3 trials.
• Total patients treated with OX2R agonists in published RCTs: under 1,000.
• Long-term safety data does not exist. Nobody knows what 5+ years of chronic orexin receptor stimulation looks like.
• These drugs will be expensive and prior authorization will be difficult.
• NT2 patients: alixorexton is your only pipeline option with Phase 2 data. Same for idiopathic hypersomnia.

Plain English Translation)

Clinical trial phases explained:

• Phase 1: First time in humans. Small (10-50 people). Tests safety and dosing, NOT whether the drug works. If a drug only has Phase 1 data, we know almost nothing about how well it treats narcolepsy.
• Phase 2: Medium-sized (50-300 people). Tests whether the drug actually works and finds the right dose. Phase 2a is early, often single-dose. Phase 2b is later, multi-week. A positive Phase 2 is real evidence but not final proof.
• Phase 3: Large (100-3,000+ people). The definitive test. Must prove the drug works against placebo in a randomized, double-blind trial (neither patient nor doctor knows who got the real drug). Phase 3 success is what gets a drug approved.

Key measurements explained:

• MWT (Maintenance of Wakefulness Test)
• ESS (Epworth Sleepiness Scale)

What the numbers mean:

• OX2R agonist: A drug that activates the orexin receptor 2. Orexin is the brain chemical that keeps you awake. Narcolepsy type 1 destroys the neurons that make orexin. An OX2R agonist replaces that missing signal. This is why these are called "disease-modifying" rather than covering up the symptoms.
• RCT: Randomized Controlled Trial. Patients are randomly assigned to drug or placebo, and neither they nor their doctors know which group they're in (double-blind). This is the gold standard for proving a drug works.
• p-value: The probability the result is random chance. p<0.05 means less than 5% chance it's noise. p<0.001 means less than 0.1% chance. Smaller p-value means stronger evidence. But p-values don't tell you how BIG the effect is. A drug can have p<0.0001 and still be barely better than placebo if the sample is huge.
• n: Number of patients in the trial. Small n means less reliable. n=22 is very low. n=200+ starts to be trustworthy.
• PMID: PubMed ID number.
• NCT number
• AE: Adverse Event. A side effect. "Serious AE" means hospitalization, disability, or life-threatening.
• Non-inferiority trial: A study designed to prove Drug A is "not meaningfully worse" than Drug B. If a new drug fails non-inferiority, it means the old drug beat it. Pitolisant failed this test against modafinil.

What "industry-funded" means:

The drug company pays for the trial. This does not mean the data is fake, but it does mean there is a financial incentive for positive results. Independent (investigator-initiated or NIH-funded) trials eliminate this conflict. Zero Phase 3 narcolepsy trials are independent. Pharma companies can choose not to publish some data since they fund it btw.

Peer-reviewed vs press release:
Peer-reviewed means independent scientists checked the data before a medical journal published it. Press release means the company announced results themselves with no outside verification. Press releases are not worthless, but they are unverified. Assume they are cherry picking the data

METHODOLOGY

Rankings based on: phase of evidence, data quality (peer-reviewed vs press release), effect size, replicability, and safety signal.

Critical limitation: zero head-to-head trials exist between pipeline drugs. Cross-trial comparisons are inherently noisy. Anyone claiming to know which drug is "best" is overstating what the data supports.

Funding: every Phase 2+ narcolepsy trial is industry-funded. Zero investigator-initiated Phase 3 trials exist. This does not invalidate the data but must be mentioned

The first time I heard Alex g I think the instrumentals was what got me. Also the raw emotion it conveyed really felt like my emotions turned into music. Tell me about the times when you guys first heard Alex G, what song, and how did you feel?

I really hope that this post is seen by anyone who Google searches issues with Mercari customer support.

So I recently made a large vintage Lego purchase of around $900, I confirmed directly with the seller whether any unique pieces were missing from the set, after I received the item I realized that unique pieces were missing. I messaged the seller saying, hey man I saw that unique pieces were missing and you confirmed with me that there weren’t. He then preceded to give me a list of the unique pieces that were missing, this means he knew that there were but he withheld that information from me. He did not put that list of missing pieces on the listing either. Also there were flies and brown residue that didn’t smell like rat fieces but I don’t even want to know what it is but it was brownish. I sent pictures of the flies in the plastic bags as well. I cleaned the brown residue but that was before I built the sets and knew I would have to return it so I couldn’t take a picture.

So I sent the pictures to Mercari and then they replied saying I need a picture of the labels and packaging you received it in. The weird thing is I already sent the pictures to them clearly of the label and the box it came in. It makes me believe they use AI for customer support. I tried to call them 3 times and they hung up every single time after 8 minutes.

Anyways so I sent the pictures again and sent pictures of all the items, I only built roughly half of the Legos in the $900 package so the other pictures were of the baggies they were in. There is no possible way at all to truly tell from a picture of Lego bags or a picture of the sets that had missing pieces if the item I received matched the listing. The weird thing is when I sent the pictures they immediately denied my claim, this makes me believe they use AI to verify these things. I even uploaded pictures of the seller admitting that he should’ve told me the list of the unique pieces missing but they said nothing about that.

In the message they said I can request if the seller will approve my return process but I have a feeling they won’t, I sent a message will update Reddit later.

So basically Mercari has no customer service, you can’t get on the phone with them, they use AI or they don’t even look at the evidence you posted. Why would I even buy from mercari if this is how customer support works? I truly recommend anyone who is thinking of buying from mercari to avoid the platform.

Edit: They denied my return. They said because it’s a lot and it doesn’t have an itemized list they can’t determine the items condition or description. They completely ignored my discussion with the seller. I’m thinking of starting a chargeback with my payment processor or escalate other ways. Also they removed my ability to rate the purchase. But I truly cannot recommend this company for buyers and sellers.

So I’ve never used mercari before but recently I was looking for this vintage Lego sets from 1998-1999. It was 11 sets in total for $900 shipping included. The seller claimed it was 99%-100% complete and as far as they knew weren’t missing any significant amount of pieces.

I was very excited to receive them and I didn’t think anything wrong the seller had a bunch of 100% positive reviews. I’ve bought various used vintage Lego sets from eBay that were missing pieces and they just give me a partial refund. I know Lego ships you replacement pieces if you say you’re missing them from a set but these are 26-27 years old. Some of the pieces they don’t make anymore and are very rare. I’ve only built like 5 of the sets so far and it’s missing like 20 pieces, 4 of them being unique to the set and very rare. I imagine the rest of the sets being bigger will have more missing pieces.

So to sum it up, is my only option to ask for a full refund and return everything? I’m just so pissed because I’ve spent hours building the sets and I’m identifying the missing pieces for the seller doing work they should’ve done. I have the back and forth texts from the seller where they confirmed with me no unique pieces are missing, and if something is missing it’s something basic. Is there no work around? If the remaining sets continue to miss significant amount of pieces the amount of money to buy those unique pieces and pieces in general would be more than a $100.

Edit: I spoke to the seller and they gave me a list of all the missing pieces after I complained. They literally lied to me in text when I confirmed with them if they had all the unique pieces and he knew that it was missing pieces. I hate humans. Is there anyway to escalate this with customer service? He could’ve literally posted saying the sets are incomplete and missing unique pieces for which he had a list but instead decided to lie hoping someone doesn’t complain. I’m done buying used Lego sets online.

Edit 2: the sellers listing claimed sets were either 99% compete or 100% complete on the listing. One of the smaller sets were missing half the pieces, much less than 99% complete, the other 4 I completed were missing a few unique pieces while he claimed they were 100% complete.

People keep saying DMs don’t matter but the matter of the fact is he knew they were missing unique pieces and he lied to me directly, after I complained after I got the package he sent me a list of all the pieces missing meaning he lied on the listing and directly to me. I don’t know if mercari checks DMs but this seller lied to me end of story. I know most of you guys are mercari sellers are trying to take his side but this is a $900 purchase, the Lego pieces were dirty, had flies, had some sort of sticky residue that was either brown paint or rat fieces and I even cleaned it for him and now he’s getting his Legos back with the missing pieces identified. If you sell something for $900 you make sure it’s as described

Exactly what the title says, every single damn time a new version comes out it fixes issues from the past and it creates new fking features that has bugs.

So if the openclaw devs frequent this sub, STOP CREATING NEW FEATURES WITHOUT FIXING ALL THE BUGS IN THE PAST. EVERY TIME YOU CREATE NEW FEATURES YOU KEEP BREAKING OPENCLAW

Like god damn at this point they have to know they create a never ending cycle of patch the bugs, release new features with bugs, rinse and repeat. It’s clear whoever the hell is releasing new versions isn’t testing it to make sure it actually works.

So can we start a petition in which openclaw stops pumping out new features without fixing the existing bugs. Openclaw is fking fine where it stands without new features, the biggest detriment to openclaw is the bugs, we don’t want more fking features that crash openclaw all the time damnit.

I apologize for my anger but every single update I spend at least an hour or two debugging whatever they did. Yes I understand it’s free but at this point it’s clear the service is useless and when competitors come out with better versions open claw will be a thing of the past unless it’s bought out

Hi guys, I’ve posted various times giving my personal experience on all medications for narcolepsy, I’ve basically tried all of them and while wakix and sodium Oxybates are game changers, the side effects can be really detrimental.

So I switched back to regular stimulants but because I’m sensitive to stimulants I can’t tolerate the peaks and crashes, higher blood pressure, higher anxiety, etc. This dilemma with stimulants has led to me try various one and I think I’ve finally found the best one for me. I truly think this is the superior stimulant for the reasons described below.

Xelstrym is Dexedrine IR but with a different method of consumption. Instead of a pill it’s a sticker patch you put on certain areas of your body. Instead of Dexedrine being affected by what you ate, higher fat meal could mean less Dexedrine or longer duration of effect, some people have malabsorption issues with medications as well, the patch absorbs through your skin and builds up and passes into your blood. The patch isn’t affected by what you ate or any malabsorption issues, it could also be a solution for people in weight loss drugs because those are known to delay absorption of medications.

The biggest pro for me is the reduced side effects. Because the medication is trickled slowly into your blood you don’t get one large dose of 10mg etc at once, you get small amounts of Dexedrine trickled into your body throughout the day. The patch also lasts longer than regular Dexedrine so it’s kind of like an extended release but better. So because it’s trickled there is no emotional peak where you feel restless or uncomfortable. My blood pressure and heart rate peaked a little but much less than with the pill. The anxiety side effect is still there but greatly diminished, I have a severe anxiety disorder and the difference is night and day. Once that slight peak for the patch hits the anxiety goes away, so the peak of the worst side effects only lasts for like 1 or 2 hours but even then it’s much more mild than pill Dexedrine.

Another huge pro is that you can take xelstrym off earlier, if you only need stimulant coverage for a few hours no problem.

One side note: I’ve noticed some people say they feel that regular stimulants like Adderall or vyvanse work better than modafinil or wakix. I feel that people are attributing the dopamine rush and emotional energy boost with wakefulness. This medication while still a potent dopamine booster will not give you the same rush some people are accustomed to. This gives you steady wakefulness which really is the goal of treatment unless you have adhd or another reason for taking it.

I really think people should ask their doctors to send prior authorizations to their insurances to see if they cover it or also just in general. There are newer stimulants available with less side effects, people shouldn’t have to take the older ones just because their doctor has never tried the newer options before.

Let me know what you guys think! Im very happy I’ve found a treatment that works for wakefulness because I couldn’t tolerate sodium Oxybates or wakix

MSOS at $4.860. Up 3.84% today.

Avg daily volume of 8.172 M over the last year, spiking to 17.6M over the last 10 days.

Beta of 1.10 against SPY, 0.85 against IWM, 0.78 against QQQ. Beta 0.12 3YR

Annualized volatility of 112%, roughly 9x the S&P 500.

NAV of $4.69, trading at a slight premium. . The 52-week range is $2.06 to $7.25.

Top Holdings:

| Holding | Weight | Revenue | Net Income | EBITDA | GM | Debt | Cash |

| ----------- | ------- | ------- | ---------- | ------ | ----- | ------- | ----- |

| Green Thumb | ~18% | $1,175M | +$114M | +$283M | 48.9% | $518M | $274M |

| Trulieve | ~15-18% | $1,181M | -$111M | +$322M | 60.2% | $565M | $256M |

| Curaleaf | ~8-10% | $1,268M | -$247M | +$222M | 49.8% | $1,037M | $102M |

| Cresco | ~5-8% | $656M | -$135M | +$126M | 49.5% | $584M | $58M |

Green Thumb is the anchor: profitable with positive FCF of $166M, clean balance sheet, P/E of 15.7. Trulieve is operationally strong at 60% gross margin and $322M EBITDA but carries net losses from debt service. Curaleaf has the most revenue but heaviest debt load.

How Rescheduling Changes Everything:

The single biggest lever is IRC 280E elimination. Currently cannabis companies can only deduct cost of goods sold, not operating expenses, forcing effective tax rates of 50 to 80%. Schedule III removes 280E and they file normal corporate taxes at roughly 21%.

Real math on Green Thumb: $1.175B revenue, $283M EBITDA, $114M net income. With 280E gone their tax bill drops from roughly $100M to roughly $22M. Net income goes from $114M to about $192M, a 68% increase from a single tax change with zero revenue growth needed. Additional benefits include normal banking access, exchange uplisting, and P/E compression toward consumer staples levels.

Options Sentiment (Weekly May 1):

OI P/C of 0.11 (56,008 calls vs 6,314 puts). Roughly 9 calls for every 1 put. A third of call OI is at the $6 strike, 24% OTM.

Delta Exposure (DEX):

| Expiry | Net DEX | Reading |

| -------- | --------- | ------- |

| May 1 | +$78,251 | Bullish |

| May 15 | +$45,355 | Bullish |

| Jun 18 | +$191,554 | Bullish |

| Sep 18 | +$55,049 | Bullish |

| Jan 2027 | +$318,877 | Bullish |

| Jan 2028 | +$81,121 | Bullish |

Every expiry is positive. Total call DEX of $892K against $100K put DEX. January 2027 alone holds $319K of structural long positioning.

Gamma Exposure (GEX):
| Strike | Net GEX | Role |

| ------ | ------- | ---------------- |

| $4.50 | +$121K | Support |

| $5.00 | +$524K | Largest anchor |

| $5.50 | +$171K | Resistance shelf |

| $6.00 | +$233K | Upside wall |

| $7.00 | +$141K | Far OTM |

Total call GEX of $1.70M against $322K put GEX. The dominant level is $5 at +$524K where dealers are long gamma and stabilize price. Support at $4.50 with $121K. Upside wall at $6 with $233K. The whole structure is positive gamma from $4.50 through $10.

Dark Pool:

Short volume at near one year lows. Week ending April 24 had 19.77% short volume with a long/short ratio of 4.06, meaning over $4 of long volume for every $1 shorted. Historical average is 35 to 45%. In mid-2025 it was above 50%. The declining trend is bullish.

Unusual Activity:

One notable trade. April 20, $510,000 premium, bought $6 calls expiring September 18 at 144 days out. At ask, bullish. Directional bet on rescheduling before September.

Todays Largest Trades (all buys):

Opening print at 9:30 AM at $4.63 for 52,119 shares for $241K on NYSE Arca. Three dark pool prints at $4.73, $4.77, and $4.80 through the morning for another $463K. All buys, accumulation at rising prices.

Correlation Data (1 year):

| vs | 1-Yr R | R2 | 60D Now | Range |

| --- | ------ | ---- | ------- | -------------- |

| SPY | +0.12 | 1.5% | +0.43 | -0.07 to +0.44 |

| QQQ | +0.11 | 1.3% | +0.44 | -0.12 to +0.45 |

| IWM | +0.15 | 2.2% | +0.42 | -0.01 to +0.47 |

| TLT | -0.02 | 0% | +0.08 | -0.32 to +0.20 |

MSOS is uncorrelated on a full year basis with over 97% of moves explained by its own sector. But the 60 day rolling correlation has surged to its highest all year at 0.43 against SPY. In January it was negative. This shift means MSOS is tracking the broad market more closely than it has all year. If it reverts to independence, sector catalysts need to reassert. If elevated correlation holds, macro is increasingly driving price.

Summary: Bullishly positioned across every expiry and every key gamma level. Dark pool shorts at one year lows. Todays flow was all buys. The rescheduling catalyst has real math behind it with net income uplift of roughly 68% from a tax change alone. The risk is the rising correlation to the broad market, which could drag MSOS down in a risk off environment even if cannabis specific factors are intact.

Not financial advice my opinion, I can be wrong, this etf is high risk, high reward, hedge accordingly and position your portfolio according to your risk tolerance